Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 36-41

  Petrillo, M ^a   Fagotti, A ^b   Ferrandina, G ^a   Fanfani, F ^a   Costantini, B ^a   Vizzielli, G ^a   Pedone Anchora, L ^a   Nero, C ^a   Margariti, P A ^a   Scambia, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Anatomic site of disease; Favourable prognosis; Localized relapse; Recurrent ovarian cancer; Secondary debulking surgery

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CYTOREDUCTIVE SURGERY; FEMALE; FEVER; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PARAAORTIC LYMPH NODE; PELVIC DISEASE; PELVIC LYMPHOCELE; POSTOPERATIVE COMPLICATION; POSTRELAPSE SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLEEN METASTASIS; TREATMENT OUTCOME; WOUND DEHISCENCE;

EID: 84885319762     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.06.020     Document Type: Article

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63: 11-30.
2. Heintz AP, Odicino F, Maisonneuve P, et al. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95:S161-92.
3. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9: 389-93.
4. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22: 3120-5.
5. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann Oncol 1997;8: 963-8.
6. Hoskin P, O'Reilly S, Swenerton K. The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer 1991;1: 205-8.
7. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer 2006;42: 2296-302.
8. Lee CK, Simes RJ, Brown C, et al. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer 2011;105: 1144-50.
9. Lee CK, Simes RJ, Brown C, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol 2013;24: 937-43.
10. Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study. Int J Gynecol Cancer 2013;23: 461-8.
11. Legge F, Petrillo M, Adamo V, Pisconti S, Scambia G, Ferrandina G. Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. BMC Cancer 2008;8:367.
12. Blanchard P, Plantade A, Pages C, et al. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol Oncol 2007;104: 41-5.
13. Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 2007;104: 686-90.
14. Uzan C, Morice P, Rey A, et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol 2004;11: 658-66.
15. Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007;109: 685-91.
16. Kaplan FL, Meier P. Non parametric estimation from incomplete observations. Am J Stat Assoc 1958;53: 457-81.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50: 163-70.
18. Cox DR. Regression models and life tables. J R Stat Soc 1972;34: 197-220.
19. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006;7: 925-34.
20. Lancaster JM, Dressman HK, Clarke JP, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006;16: 1733-45.
21. Bignotti E, Tassi RA, Calza S, et al. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol 2007;196:245.e1-245.e11.
22. Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2010:CD007822.
23. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106: 1933-9.